A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
Public ClinicalTrials.gov record NCT00162123. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Study identification
- NCT ID
- NCT00162123
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 248 participants
Conditions and interventions
Conditions
Interventions
- Ipilimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Aug 31, 2012
- Completion
- Mar 31, 2014
- Last update posted
- Jul 26, 2016
2006 – 2014
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| Wilshire Oncology Medical Group Inc | Laverne | California | 91750 | — |
| The Angeles Clinic & Research Inst. | Los Angeles | California | 90025 | — |
| Usc/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| San Francisco Oncology Associates | San Francisco | California | 94115 | — |
| Local Institution | To Come | Connecticut | — | — |
| Baptist Cancer Institute | Jacksonville | Florida | 32207 | — |
| University Of Chicago | Chicago | Illinois | 60637 | — |
| Indiana Oncology Hematology Consultants | Indianapolis | Indiana | 46202 | — |
| St Joseph Oncology Inc | Saint Joseph | Missouri | 64507 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| The Christ Hospital Cancer Center Research | Cincinnati | Ohio | 45219 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Cancer Centers Of The Carolinas | Greenville | South Carolina | 29615 | — |
| Center For Oncology Research & Treatment, P.A. | Dallas | Texas | 75230 | — |
| Joe Arrington Cancer Research And Treatment Center | Lubbock | Texas | 79410 | — |
| University Of Washington Medical Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00162123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00162123 live on ClinicalTrials.gov.